ISCO Completes $25.25M Sale of Lifeline Cell Technology, Books $19.3M After-Tax Gain
ISCO has more than doubled off its 52-week low of $0.081.
Summary
ISCO completed the $25.25 million sale of Lifeline Cell Technology, receiving $21.7 million in net cash and booking a $19.3 million after-tax gain that eliminates its stockholders' deficit.
Key Events · M&A and Partnerships · ISCO
-
LCT Sale Completed
Closed the sale of Lifeline Cell Technology to ATCC on September 1, 2026 for an adjusted purchase price of $25.25 million.
-
Net Cash Proceeds
Received $21.7 million in net cash at closing after $2.6 million escrow holdback and $1.0 million in transaction costs.
-
After-Tax Gain
Recognized an estimated after-tax gain of $19.3 million, credited directly to accumulated deficit, eliminating the stockholders' deficit.
-
Pro Forma Impact
Pro forma balance sheet shows total assets of $26.3 million and stockholders' equity of $17.7 million as of June 30, 2026.
Analysis · ISCO · Life Sciences
International Stem Cell Corporation closed the sale of its Lifeline Cell Technology subsidiary on September 1, 2026, receiving net cash proceeds of $21.7 million and recognizing an after-tax gain of $19.3 million. The transaction transforms the company's balance sheet, eliminating its stockholders' deficit and providing substantial cash runway for its remaining therapeutic research and development operations. The pro forma financials show the company's continuing operations generated only $296,000 in revenue for the first half of 2026, highlighting the strategic importance of this divestiture.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 36.1% of the 1753 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ISCO was trading at $0.33 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $0.08 to $0.54. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.